1.Evaluation of the predictive effect of PD-L1 expression on survival in early triple-negative breast cancer.
Jian YUE ; Xue WANG ; An Jie ZHU ; Ding Yuan WANG ; Song Lin GAO ; Nan Lin HU ; Yi Ran SI ; Fang Chao ZHENG ; Jie JU ; Zheng WANG ; Peng YUAN
Chinese Journal of Oncology 2023;45(11):948-954
Objectives: To find the prognostic factors related to early triple-negative breast cancer to optimize the therapeutic strategies, and explore the influence of programmed cell death ligand-1(PD-L1)expression in early triple-negative breast cancer on its prognosis, so as to provide support for clinical treatment decisions. Methods: Early triple-negative breast cancer patients treated at the National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences during 1st June, 2009 and 31st Oct, 2015 were enrolled in this study. All the clinicopathological data of patients were collected, and the paraffin sections of the surgical specimens were stained with estrogen receptor, progesterone receptor, human epidermal growth factor receptor-2, secreted protein acidic and rich in cysteine (SPARC), androgen receptor, PD-L1 and other antibodies by the immunohistochemical method. Kaplan-Meier survival and Cox regression curves were used for survival analysis of relevant clinical and pathological results and nomogram survival prediction models were established to explore the influence of relevant factors on the prognosis. Results: A total of 205 patients with triple-negative breast cancer were enrolled. Ninety patients (43.9%) were PD-L1 positive. The median follow-up time was 63 months. Thirty-seven patients were relapsed or recurrent and 16 patients were dead. The 5-year disease-free survival (DFS) rate and overall survival (OS) rate were 86.1% (95% CI: 81.4%-90.8%) and 93.6% (95% CI: 91.0%-97.6%), respectively, in the general population. Univariate Cox regression analysis showed that PD-L1 expression and lymph node metastasis were correlated with DFS and OS (P<0.05). In multivariate analysis, PD-L1 expression was an independent influencing factor of DFS, with PD-L1 positive patients possessing a significant survival benefit in DFS (HR=0.31, 95% CI: 0.13-0.73). Lymph node metastasis was an independent influencing factor of OS, and OS was significantly shortened in patients with positive lymph node metastasis (HR=3.24, 95% CI: 1.15-9.17). PD-L1, lymph node metastasis, menopausal status, Ki-67 index and adjuvant chemotherapy regimen were included to establish the 1- and 3-year DFS and OS nomogram prediction models, resulting in C indices of 0.698 and 0.748, respectively. Conclusions: PD-L1 expression is a predictive biomarker of good prognostic factor in triple-negative breast cancer patients. DFS is significantly prolonged in PD-L1 positive patients and OS also shows a prolongation trend. The nomogram prognosis prediction models have reference values for adjuvant chemotherapy in this patient group.
Humans
;
Female
;
Lymphatic Metastasis
;
B7-H1 Antigen/metabolism*
;
Triple Negative Breast Neoplasms/pathology*
;
Breast Neoplasms
;
Osteonectin/therapeutic use*
;
Prognosis
2.Evaluation of the predictive effect of PD-L1 expression on survival in early triple-negative breast cancer.
Jian YUE ; Xue WANG ; An Jie ZHU ; Ding Yuan WANG ; Song Lin GAO ; Nan Lin HU ; Yi Ran SI ; Fang Chao ZHENG ; Jie JU ; Zheng WANG ; Peng YUAN
Chinese Journal of Oncology 2023;45(11):948-954
Objectives: To find the prognostic factors related to early triple-negative breast cancer to optimize the therapeutic strategies, and explore the influence of programmed cell death ligand-1(PD-L1)expression in early triple-negative breast cancer on its prognosis, so as to provide support for clinical treatment decisions. Methods: Early triple-negative breast cancer patients treated at the National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences during 1st June, 2009 and 31st Oct, 2015 were enrolled in this study. All the clinicopathological data of patients were collected, and the paraffin sections of the surgical specimens were stained with estrogen receptor, progesterone receptor, human epidermal growth factor receptor-2, secreted protein acidic and rich in cysteine (SPARC), androgen receptor, PD-L1 and other antibodies by the immunohistochemical method. Kaplan-Meier survival and Cox regression curves were used for survival analysis of relevant clinical and pathological results and nomogram survival prediction models were established to explore the influence of relevant factors on the prognosis. Results: A total of 205 patients with triple-negative breast cancer were enrolled. Ninety patients (43.9%) were PD-L1 positive. The median follow-up time was 63 months. Thirty-seven patients were relapsed or recurrent and 16 patients were dead. The 5-year disease-free survival (DFS) rate and overall survival (OS) rate were 86.1% (95% CI: 81.4%-90.8%) and 93.6% (95% CI: 91.0%-97.6%), respectively, in the general population. Univariate Cox regression analysis showed that PD-L1 expression and lymph node metastasis were correlated with DFS and OS (P<0.05). In multivariate analysis, PD-L1 expression was an independent influencing factor of DFS, with PD-L1 positive patients possessing a significant survival benefit in DFS (HR=0.31, 95% CI: 0.13-0.73). Lymph node metastasis was an independent influencing factor of OS, and OS was significantly shortened in patients with positive lymph node metastasis (HR=3.24, 95% CI: 1.15-9.17). PD-L1, lymph node metastasis, menopausal status, Ki-67 index and adjuvant chemotherapy regimen were included to establish the 1- and 3-year DFS and OS nomogram prediction models, resulting in C indices of 0.698 and 0.748, respectively. Conclusions: PD-L1 expression is a predictive biomarker of good prognostic factor in triple-negative breast cancer patients. DFS is significantly prolonged in PD-L1 positive patients and OS also shows a prolongation trend. The nomogram prognosis prediction models have reference values for adjuvant chemotherapy in this patient group.
Humans
;
Female
;
Lymphatic Metastasis
;
B7-H1 Antigen/metabolism*
;
Triple Negative Breast Neoplasms/pathology*
;
Breast Neoplasms
;
Osteonectin/therapeutic use*
;
Prognosis
3.Analysis of chloroplast genomes and development of specific DNA barcodes for identifying the original species of Rhei Radix et Rhizoma
Ran-jun LI ; Li-wei WU ; Tian-yi XIN ; Hai LIAO ; Yu-lin LIN ; Hui YAO ; Jia-yu ZHOU ; Jing-yuan SONG
Acta Pharmaceutica Sinica 2022;57(5):1495-1505
Rhei Radix et Rhizoma is one of the most used medicinal materials in China. Its original species are
4.Vasorelaxant effect and mechanisms of compound reserpine and triamterene tablets on the isolated thoracic aorta rings
Di-fei GONG ; Ran-ran WANG ; Tian-yi YUAN ; Shou-bao WANG ; Jun-ke SONG ; Lian-hua FANG ; Guan-hua DU
Acta Pharmaceutica Sinica 2022;57(11):3339-3344
This study aimed to evaluate the vasorelaxant effect and mechanisms of compound reserpine and triamterene tablets (CRTTs) and its component triamterene on isolated rat thoracic aorta rings. Isolated rat thoracic aorta rings pre-contracted by high potassium or norepinephrine (NE) were used to evaluate the vasodilatory effect of CRTTs and its component triamterene. The mechanisms concerning endothelium, potassium channels and calcium channels were studied through the interventions of several tool drugs. Animal welfare and experimental procedures followed the requirements of the Laboratory Animal Management and Animal Welfare Ethics Committee of the Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College. The results showed that both CRTTs and triamterene had potent relaxant effect on KCl and NE pre-contracted vessels. Triamterene showed partial endothelium dependency, and
5.Pharmacy active consultation:an innovative model of hospital pharmaceutical services
Qian DU ; Xin XI ; Jie DONG ; Jun ZHU ; Guili HUANG ; Jinghui GOU ; Hailong RAN ; Cheng CHEN ; Zhanfeng BAI ; Dongxuan LI ; Yuzhu DONG ; Wenjun LI ; Yi SONG ; Songqing LIU
China Pharmacy 2022;33(21):2666-2670
Pharmacy active consultation refers to the spontaneous activity that clinical pharmacists take the initiative to go to clinical departments to help doctors solve problems related to drug use in clinical practice ,put forward drug treatment suggestions or provide pharmaceutical services ,and form medical documents . The difference between pharmacy active consultation and pharmacy consultation is that the latter is generally proposed by the clinician ,who sends a consultation invitation to the pharmacy department in the hospital information system ,and the clinical pharmacist will go to the consultation after receiving it ,while the former is a pharmaceutical service mode that the clinical pharmacist takes the initiative to carry out in the clinical department . On the basis of routine pharmacy active consultation ,clinical pharmacists in our hospital also further carried out a special active consultation mode (including prompt special active consultation for patients with multidrug resistance bacteria positive ,active monitoring and intervention for patients with drug -induced liver injury ),and patient pharmaceutical supervision in the form of return visit of pharmacy active consultation . Pharmacy active consultation and its special active consultation possess the characteristics of initiative , early and extensive coverage ,as a supplement to resident clinical pharmacy services . Pharmacy active consultation could help the pharmacy department to improve service efficiency ,provide a new perspective for medical institutions to carry out efficient pharmaceutical services ,and supply new ideas for the reform of pharmaceutical services in China .
7.DEFB126 polymorphisms and association with idiopathic asthenozoospermia in China.
Jiao-Yu HE ; Jian-Ying PENG ; Qiu-Fu LI ; Xiao-Li LIN ; Yan-Ru CUI ; Shi-Yu MA ; Shi-Yun FAN ; Yi-Ran LIU ; Zhi-Lin SONG ; Jun-Hang DENG ; Xia WEI ; Xian-Ping DING
Asian Journal of Andrology 2022;24(6):607-614
Idiopathic asthenozoospermia, a common factor in male infertility, is characterized by altered sperm motility function in fresh ejaculate. Although the β-defensin 126 (DEFB126) protein is associated with asthenozoospermia, DEFB126 gene polymorphisms have not been extensively studied. Therefore, the association between DEFB126 gene polymorphisms and asthenozoospermia requires further investigation. Screening was performed by semen analysis, karyotype analysis, and Y microdeletion detection, and 102 fertile men and 106 men with asthenozoospermia in Chengdu, China, were selected for DEFB126 gene sequence analyses. Seven nucleotide mutations and two nucleotide deletions in the DEFB126 gene were detected. rs11467417 (317-318 del/del), rs11467497 (163-166 wt/del), c.152T>C, and c.227A>G were significantly different between the control and asthenozoospermia groups, likely representing high-risk genetic factors for asthenozoospermia among males. DEFB126 expression was not observed in sperm with rs11467497 homozygous deletion and was unstable in sperm with rs11467417 homozygous deletion. The rs11467497 four-nucleotide deletion leads to truncation of DEFB126 at the carboxy-terminus, and the rs11467417 binucleotide deletion produces a non-stop messenger RNA (mRNA). The above deletions may be responsible for male hypofertility and infertility by reducing DEFB126 affinity to sperm surfaces. Based on in silico analysis, the amino acids 51M and 76K are located in the highly conserved domain; c.152T>C (M51T) and c.227A>G (K76R) are predicted to be damaging and capable of changing alternative splice, structural and posttranslational modification sites of the RNA, as well as the secondary structure, structural stability, and hydrophobicity of the protein, suggesting that these mutations are associated with asthenozoospermia.
Male
;
Humans
;
Asthenozoospermia/metabolism*
;
Sperm Motility/genetics*
;
Homozygote
;
Polymorphism, Single Nucleotide
;
Semen
;
Sequence Deletion/genetics*
;
Spermatozoa/metabolism*
;
Nucleotides/metabolism*
;
beta-Defensins/metabolism*
8.Research progress in original species identification in industry chain of Rhei Radix et Rhizoma.
Ran-Jun LI ; Tian-Yi XIN ; Liang-Ke SONG ; Hai-Xia YAN ; Hai LIAO ; Jia-Yu ZHOU ; Jing-Yuan SONG
China Journal of Chinese Materia Medica 2021;46(5):1060-1066
Rhei Radix et Rhizoma is a kind of commonly used Chinese medicinal materials. Due to the overharvesting, the wild resource is endangering. Large market demand caused severely adulterant of commercial Rhei Radix et Rhizoma medicinal materials and decoction pieces. This manuscript reviewed the advances of the original species authentication in the industrial chain of Rhei Radix et Rhizoma during the latest decade, including characteristics and microscopic features, phytochemical analysis on anthraquinones, and molecular authentication based on DNA barcoding. Accordingly, an original species authentication route for the industrial chain of Rhei Radix et Rhizoma was summarized:(1)the identification of seeds and seedlings by DNA barcoding;(2) the selection of high variable sites based on the chloroplast genome;(3)biomonitoring of the Rhei Radix et Rhizoma medicinal materials and decoction pieces by two-dimensional DNA barcode;(4)traceability of Chinese patent medicines by third-generation sequencing. In conclusion, the combination of molecular identification and traditional identification methods provides a new idea for the identification of the original species of Rhei Radix et Rhizoma in the industrial chain and a essential guidance for the research of drug safety and efficacy of Rhei Radix et Rhizoma.
Animals
;
Anthraquinones
;
Drugs, Chinese Herbal
;
Plant Roots
;
Rheum
;
Rhizome
9.DNA barcoding identification of commercial decoctions in traditional Chinese medicine
Tian-yi XIN ; Qian LOU ; Li-jun HAO ; Ran-jun LI ; Yu-lin LIN ; Wen-jie XU ; Ting-yu MA ; Ye-xuan LIN ; Yi-xin DONG ; Cheng-yu JIANG ; Jing-yuan SONG
Acta Pharmaceutica Sinica 2021;56(3):879-889
Although the guiding principles for molecular identification of traditional Chinese medicines (TCM) using DNA barcoding have been recorded in the Chinese Pharmacopoeia, there is still a lack of systematic research on its application to commercial TCM decoctions. In this study, a total of 212 commercial TCM decoctions derived from different medicinal parts such as root and rhizome, fruit and seed, herb, flower, leaf, cortex, and caulis were collected to verify applicability and accuracy of the method. DNA barcodes were successfully obtained from 75.9% (161/212) of the samples, while other samples failed to be amplified due to genomic DNA degradation. Among the 161 samples, 85.7% of them were identified as recorded species in the Chinese Pharmacopoeia (2020 edition). In addition, 14 samples could be identified as species recorded in the Chinese Pharmacopoeia and their closely related species in the same genus. Morphological identification for the unconfirmed samples showed that eight were genuine species and three were adulterants, while the other three were unidentifiable due to lack of morphological characteristics. Furthermore, the DNA barcodes of seven samples accurately mapped to the sequences of adulterants. Remarkably, counterfeit products were detected in two samples. These results demonstrate that DNA barcoding is suitable for the identification of commercial TCM decoctions. The method can effectively detect adulterants and is appropriate for use throughout the industrial chain of TCM production and distribution, and by the supervisory agencies as well.
10.Application of DNA barcoding technology to national drug sampling inspection
Tian-yi XIN ; Hai-xia YAN ; Ran-jun LI ; Qian LOU ; Li-jun HAO ; Bao-sheng LIAO ; Ying LIU ; Jing CHEN ; You-gen CHEN ; Xiao-wei DU ; Hong-zhu GUO ; Xin-tong FU ; Jing-yuan SONG
Acta Pharmaceutica Sinica 2021;56(5):1497-1508
Adulterants and counterfeits were found in some of the commercial traditional Chinese medicine (TCM) decoctions in Hongjin Xiaojie Jiaonang, Hongjin Xiaojie Pian, and Chaihuang Keli during the national drug sampling inspection. However, it was difficult to determine the species of the adulterants and counterfeits by conventional testing methods. Therefore, a total of 184 samples of the TCM decoctions and raw materials belong to the prescriptions of above mentioned traditional Chinese patent medicines, including Bupleuri Radix, Bajiaolian, Heimayi, and Shufuchong, were collected and authenticated by DNA barcoding technology. 111 ITS2 sequences were obtained from 115 commercial TCM decoctions and raw materials of Bupleuri Radix, among which 71 were

Result Analysis
Print
Save
E-mail